Pacira BioSciences, Inc. Free Cash Flow 2009–2025
Pacira BioSciences, Inc. reported $136.66M of free cash flow for fiscal 2025. That was 23.5% lower than fiscal 2024. Compared with fiscal 2020, the change was +248.3%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $136.66M | -23.5% |
| FY 2024 | $178.75M | +28.1% |
| FY 2023 | $139.49M | +21.1% |
| FY 2022 | $115.20M | +44.3% |
| FY 2021 | $79.85M | +103.5% |
| FY 2020 | $39.23M | -35.0% |
| FY 2019 | $60.36M | +75.7% |
| FY 2018 | $34.36M | +2419.8% |
| FY 2017 | $-1.48M | -116.9% |
| FY 2016 | $8.74M | +171.2% |
| FY 2015 | $-12.27M | -442.8% |
| FY 2014 | $3.58M | +106.4% |
| FY 2013 | $-56.01M | +36.6% |
| FY 2012 | $-88.39M | -137.8% |
| FY 2011 | $-37.17M | -17.4% |
| FY 2010 | $-31.65M | -20.1% |
| FY 2009 | $-26.35M | — |
Source: Pacira BioSciences, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open PCRX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Pacira BioSciences, Inc. reported $136.66M of free cash flow for fiscal 2025. That was 23.5% lower than fiscal 2024. Compared with fiscal 2020, the change was +248.3%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Pacira BioSciences, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freePacira BioSciences, Inc. — frequently asked questions
What is Pacira BioSciences, Inc.'s free cash flow?
Pacira BioSciences, Inc. (PCRX) reported free cash flow of $136.66M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Pacira BioSciences, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.